Jan Cosaert

Title: Jan Cosaert: Innovator in Pharmaceutical Combinations

Introduction

Jan Cosaert is a notable inventor based in Wommelgem, Belgium. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative drug combinations. His work focuses on addressing proliferative diseases through targeted therapies.

Latest Patents

Jan Cosaert holds a patent for "Synergistic combinations of PI3K- and MEK-inhibitors." This patent describes a pharmaceutical combination that includes a phosphatidylinositol 3-kinase (PI3K) inhibitor and at least one mitogen-activated protein kinase (MEK) inhibitor. The combination is designed for simultaneous, separate, or sequential administration, with applications in treating proliferative diseases. The patent outlines methods for administering a therapeutically effective amount of this combination to patients suffering from such conditions. He has 1 patent to his name.

Career Highlights

Jan Cosaert is currently associated with Novartis AG, a leading global healthcare company. His role involves research and development in the pharmaceutical sector, where he applies his expertise to create innovative treatment options. His contributions have been instrumental in advancing therapeutic strategies for various diseases.

Collaborations

Throughout his career, Jan has collaborated with esteemed colleagues, including Christine Fritsch and Xizhong Huang. These partnerships have fostered a collaborative environment that enhances the development of effective pharmaceutical solutions.

Conclusion

Jan Cosaert is a prominent figure in the pharmaceutical industry, recognized for his innovative approaches to drug development. His work continues to impact the treatment of proliferative diseases, showcasing the importance of collaboration and innovation in healthcare.